,i #aaith ,,congress #ast ,session ,h4 ,r4 #ecaf ,,in ,,the ,,house ,,of ,,representatives ,september #aa1 #bjbe,mrs4 ,harshbarger 7for herself and ,mr4 ,carter of ,georgia7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to ensure patients have access to certain shortage and urgent-use compounded medications1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,drug ,shortage ,compounding ,patient ,access ,act of #bjbe4 #b4 ,pharmacy compounding 7a7 ,compounding for urgent administration to patients ,section #ejc;,a7a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cec;a7a77 is amended-- 7#a7 in paragraph 7#a71 by striking or at the end2 7#b7 in paragraph 7#b77;,b77ii77,,ii71 by striking the period at the end and inserting 2 or2 and 7#c7 by adding at the end the following3 7#c7 notwithstanding the requirement in the matter preceding paragraph 7#a7 that the drug product is compounded for an identified individual patient based on a valid prescription order or notation described in such matter1 is by a licensed pharmacist or licensed physician and the compounded drug product is compounded for distribution in limited quantities to a licensed prescriber for urgent administration to a patient in a hospital or other clinical setting1 provided that all of the following are met3 7,a7 ,the drug product appeared on the drug shortage list in effect under section #ejf;,e at any time during the #fj-;day period ending on the date of the compounding1 distribution1 or dispensing of the drug product4 7,b7 ,the licensed prescriber certifies by notation on the order to the compounding pharmacist or physician that the licensed prescriber has made reasonable attempts to obtain1 and has not been able to obtain1 to address the urgent medical need a drug product that is compounded by an outsourcing facility in accordance with section #ejc;,b with the same active ingredient and the same route of administration4 7,c7 ,the compounded drug product is labeled with a beyond-use-date in accordance with applicable ,united ,states ,pharmacopeia standards4 7,d7 ,the licensed pharmacist or licensed physician marks the packaging of the compounded drug product with text-- 7i7 indicating that the drug product is provided to the hospital or other clinical setting only for urgent administration to a patient2 and 7ii7 requesting that the hospital or other clinical setting provide to the compounding pharmacist or physician the records that identify the patient or patients to whom the drug products were administered within-- 7,i7 #g days of each such patient receiving such medication2 or 7,,ii7 #g days of each such patient being discharged4 7,e7 ,upon receipt of records requested pursuant to subparagraph 7,d77ii71 the licensed pharmacist or licensed physician ensures that the patient information in such records is linked with the respective order4 7,f7 ,the licensed pharmacist or licensed physician reports adverse events associated with the compounded drug product as soon as possible but not later than #ae days after becoming aware of such events to the ,med,watch ,adverse ,event ,reporting program of the ,food and ,drug ,administration 7or any successor program74 4 7b7 ,definition ,paragraph 7#b7 of section #ejc;,a7b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cec;a7b77#b77 is amended to read as follows3 7#b7 ,definition ,for purposes of paragraph 7#a77;,d71 the term essentially a copy of a commercially available drug product does not include-- 7,a7 a drug product in which there is a change1 made for an identified individual patient1 which produces for that patient a significant difference1 as determined by the prescribing practitioner1 between the compounded drug and the comparable commercially available drug product2 or 7,b7 a drug product that meets each of the following conditions3 7i7 ,at any time during the #fj-;day period ending on the date of the compounding1 distribution1 or dispensing1 the drug product appeared on the drug shortage list in effect under section #ejf;,e4 7ii7 ,if the drug product is not compounded for an identified individual patient based on a valid prescription order or notation1 notwithstanding such requirement in the matter preceding paragraph 7#a7 of subsection 7a71 the drug product-- 7,i7 is labeled in accordance subparagraphs 7,c7 and 7,d7 of subsection 7a77#c72 and 7,,ii7 is documented by the compounding pharmacist or physician in accordance with subparagraphs 7,e7 and 7,f7 of subsection 7a77#c74 4 #c4 ,mitigating drug shortages through improved reporting ,section #ejf;,c of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef;c7 is amended-- 7#a7 in the section heading1 by inserting ,,or ,,surge ,,in ,,demand ,,for after ,,production ,,of2 7#b7 in subsection 7a71 in the matter following paragraph 7#b7-- 7,a7 by striking or an interruption of the manufacture of the drug and inserting 1 an interruption of the manufacture of the drug1 or a surge in demand for the drug2 7,b7 by striking such discontinuance or interruption and inserting such discontinuance1 interruption1 or surge in demand2 7,c7 by striking the discontinuation or interruption and inserting the discontinuation1 interruption1 or surge in demand2 7,d7 by striking such discontinuation or interruption1 the source and inserting such discontinuation1 interruption1 or surge in demand1 the source2 and 7,e7 by striking such discontinuation or interruption2 the expected duration of the interruption2 and inserting such discontinuation1 interruption1 or surge in demand2 the expected duration of the interruption or surge in demand2 7#c7 in subsection 7b71 by striking paragraphs 7#a7 and 7#b7 and inserting the following3 7#a7 in the case of a notice of a discontinuance or interruption in the manufacture of a drug-- 7,a7 at least #f months prior to the date of the discontinuance or interruption2 or 7,b7 if compliance with subparagraph 7,a7 is not possible1 as soon as practicable2 or 7#b7 in the case of a notice of a surge in demand for a drug1 as soon as practicable4 2 7#d7 in subsection 7c7-- 7,a7 by striking discontinuance or interruption and inserting discontinuance1 interruption1 or surge in demand2 and 7,b7 by inserting and outsourcing facilities 7as defined in section #ejc;,b7d77 after patient organizations2 and 7#e7 in subsection 7h7-- 7,a7 in paragraph 7#a71 by striking and that is subject to section #ejc7;b77#a7 and inserting or the active pharmaceutical ingredient of such a drug2 7,b7 by amending paragraph 7#b7 to read as follows3 7#b7 the term drug shortage or shortage1 with respect to a drug1 means a period of time with the demand or projected demand for the drug within the ,united ,states exceeds the supply of the drug1 taking into consideration-- 7,a7 how the drug is prepared or dispensed1 including the route of administration and dosage form2 and 7,b7 information reported by manufacturers1 health care professionals1 and patients2 4 7,c7 in paragraph 7#c77;,b71 by striking the period at the end and inserting 2 and2 and 7,d7 by adding at the end the following3 7#d7 the term surge means an increase in demand or projected demand for a drug that the manufacturer likely will be unable to meet without meaningful shortfall or delay4 4 #d4 ,outsourcing facility compounding ,section #ejc;,b of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cec;b7 is amended-- 7#a7 in subsection 7a77#b77;,a77ii7-- 7,a7 by striking appears and inserting appeared2 and 7,b7 by striking at the time of and inserting at any time during the #ahj-;day period ending on the date of 2 7#b7 in subsection 7a77#aj77;,a77iii7-- 7,a7 in subclause 7,,viii71 by striking the semicolon at the end and inserting 2 and2 7,b7 by striking subclause 7,,ix72 and 7,c7 by redesignating subclause 7,x7 as subclause 7,,ix72 7#c7 by redesignating the #b subsections 7d7 7relating to definitions and relating to obligation to pay fees7 as subsections 7e7 and 7f71 respectively2 and 7#d7 by inserting after subsection 7c7 the following3 7d7 ,list of identified bulk drug substances ,the ,secretary shall make publicly available annual updates on the evaluation of bulk drug substances for purposes of the list maintained under subsection 7a77#b77;,a77i74 2 #e4 ,clarifying provisions2 labeling requirement ,section #ejc;,a of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cec;a7 is amended-- 7#a7 by striking subsection 7b77#c77;,b7 and the matter following such subsection and inserting the following3 7,b7 such drug product is labeled as follows3 ,this medication has been compounded for dispensing to an individual patient and has not been approved by the ,food and ,drug ,administration4 2 and 7#b7 in subsection 7b77#a77;,a77i77,i7 by striking ,national ,formulary monograph and inserting ,national ,formulary drug or dietary supplement monograph4